Therapeutic Advances in Bile-Acid Receptor Modulation

Abstract

Bile-acid receptor modulation has emerged as a promising therapeutic avenue for a range of hepatic, metabolic, and gastrointestinal disorders. This comprehensive review explores the latest advances in bile-acid receptor-targeted therapies, focusing on underlying mechanisms, disease burden, clinical features, diagnostic approaches, and recent clinical trials. Emphasis is placed on the clinical implications for hepatologists and gastroenterologists, guidelines-based recommendations, and the translational potential of novel agents, including farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5) agonists.

Introduction

Bile acids, once considered simple detergents for dietary fat emulsification, have been redefined as potent signaling molecules modulating a spectrum of metabolic and inflammatory pathways through receptors such as FXR, TGR5, and others. Dysregulation of bile-acid signaling underpins the pathophysiology of cholestatic liver diseases, nonalcoholic fatty liver disease (NAFLD), and metabolic syndrome. Therapeutic strategies targeting these receptors are reshaping management paradigms in hepatology and metabolic medicine.

Epidemiology / Disease Burden

The burden of diseases linked to bile-acid dysregulation is substantial. Primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC) collectively affect tens of thousands worldwide, often progressing to cirrhosis and liver failure. NAFLD, now the most prevalent chronic liver disorder globally, affects approximately 25% of adults, with a subset developing nonalcoholic steatohepatitis (NASH) marked by hepatocellular injury and fibrosis. Metabolic syndrome, closely tied to bile-acid receptor signaling, is a major risk factor for cardiovascular morbidity and mortality.

Pathophysiology

Bile acids exert their effects by activating nuclear and membrane-bound receptors, primarily FXR and TGR5. FXR, expressed in hepatocytes and enterocytes, regulates bile-acid synthesis, lipid metabolism, and glucose homeostasis. TGR5, a G-protein-coupled receptor, mediates anti-inflammatory and metabolic effects in macrophages, intestines, and brown adipose tissue. Disruption of these signaling pathways leads to altered bile-acid homeostasis, hepatocellular injury, immune dysregulation, and fibrogenesis, as observed in cholestatic and metabolic liver diseases.

Risk Factors

Genetic predispositions, such as polymorphisms in NR1H4 (encoding FXR), environmental factors, high-fat diets, obesity, insulin resistance, and gut dysbiosis are key risk factors for disorders involving bile-acid receptor dysfunction. Autoimmune mechanisms contribute significantly to PBC and PSC, while metabolic syndrome and type 2 diabetes mellitus are closely associated with NAFLD and NASH.

Clinical Features

Clinical manifestations depend on the underlying disease. PBC and PSC typically present with chronic cholestasis, pruritus, fatigue, and biochemical evidence of liver injury. NAFLD is often asymptomatic until advanced fibrosis develops, where patients may present with hepatomegaly, steatosis, and features of metabolic syndrome. In advanced cases, complications such as portal hypertension, cirrhosis, and hepatocellular carcinoma can develop.

Diagnosis

Diagnosis relies on a combination of clinical, biochemical, serological, and imaging findings. Liver biochemistry demonstrates cholestatic patterns (elevated alkaline phosphatase and gamma-glutamyl transferase) in PBC/PSC. Autoantibody profiling (e.g., anti-mitochondrial antibodies) aids in PBC diagnosis. Imaging modalities, including magnetic resonance cholangiopancreatography (MRCP), are essential for PSC. In NAFLD, ultrasonography, transient elastography, and liver biopsy remain diagnostic cornerstones. Non-invasive biomarkers reflecting bile-acid metabolism are under investigation.

Treatment & Management

First-line therapy for PBC is ursodeoxycholic acid (UDCA), which improves biochemical markers and delays progression. Obeticholic acid (OCA), a selective FXR agonist, is approved for UDCA-inadequate responders. In PSC, management is largely supportive, with liver transplantation reserved for end-stage disease. For NAFLD/NASH, lifestyle modification remains central, but pharmacotherapies targeting bile-acid receptors are in advanced stages of development. Pruritus management may include bile-acid sequestrants and rifampicin.

Recent Advances / Emerging Therapies

OCA has demonstrated efficacy in PBC and NASH, improving liver histology and reducing fibrosis progression. Cilofexor and tropifexor, novel non-steroidal FXR agonists, are under clinical investigation, showing promising anti-inflammatory and anti-fibrotic effects in phase II/III trials. TGR5 agonists are in development for metabolic and cholestatic disorders, exploiting their glucose-lowering and anti-inflammatory properties. Dual FXR/TGR5 agonists represent a next-generation strategy, aiming for synergistic benefits. Safety concerns, such as pruritus and lipid profile alterations, necessitate careful patient monitoring.

Guideline Recommendations

Recent guidelines from EASL and AASLD endorse UDCA as first-line for PBC, with OCA as an adjunct in non-responders. For NASH, pharmacotherapy—preferably within clinical trials—is recommended for patients with biopsy-proven fibrosis, with FXR agonists featured as investigational options. There is an emphasis on individualized, risk-based therapeutic approaches, considering comorbidities and hepatic function.

Conclusion

Bile-acid receptor modulation has ushered in a transformative era in the management of cholestatic and metabolic liver diseases. Advances in FXR and TGR5 agonists offer new hope for patients with limited therapeutic options. Ongoing research will further clarify the optimal use, long-term safety, and expanded indications of these agents. Clinicians should stay abreast of evolving evidence and guideline updates to provide tailored, mechanism-based care for affected individuals.